Australia Daily Briefing

The Market Herald's close-of-business report confirmed that Friday's ASX session ended with the dual-drag of mining (BHP -1.27%, RIO -0.40%) and banking (Macquarie -0.93%) offset by healthcare (CSL +0.90%) and defensive consumer names. The resources rout is structurally linked to China's Q4 steel demand trajectory: iron ore spot held near $108/t but forward curve pricing was lower, suggesting futures markets are pricing in a demand adjustment that spot has not yet reflected — a basis divergence that typically resolves by the spot price moving to meet the futures signal. For ASX index positioning, the resources-vs-banks divergence story is the dominant Q4 theme: the index is a commodity-heavy/bank-heavy structure, and both sectors now carry near-term headwinds simultaneously — the first time since mid-2024 that ASX's two largest sector weights have both been in simultaneous drawdown.

Smallcaps.com.au reported that Clarity Pharmaceuticals has been granted FDA Breakthrough Therapy Designation for its copper-64 (64Cu) SAR-bisPSMA prostate cancer theranostic program — a significant regulatory milestone that typically accelerates review timelines and enables more intensive FDA guidance during development. The designation applies to Clarity's SAR-bisPSMA program in patients with metastatic castration-resistant prostate cancer, one of the highest-unmet-need oncology indications globally. Clarity is an ASX-listed micro-cap in the radiopharmaceutical space — a sector that has attracted significant institutional attention since Eli Lilly's $1.4B acquisition of a theranostics platform in 2024 set a precedent for M&A activity in the space. The BTD status puts Clarity in the peer group with Point Biopharma (acquired by Eli Lilly) and RayzeBio (acquired by Bristol-Myers Squibb) — ASX investors should track its Phase 2 readout timeline as a potential acquisition catalyst.

The Age Business and Sydney Morning Herald ran parallel feature analyses Friday examining the precedent-setting nature of the Jensen Huang resignation, placing it in the context of a documented pattern of tech and industrial CEOs whose personal conduct created national security and board governance complications. For ASX investors, the story carries a direct read-through: the articles noted that Australian super funds collectively hold approximately AUD 2.1 billion in Nvidia shares across direct and ETF exposures, making the CEO transition a material portfolio event for Australian retirement savings. The governance angle is particularly resonant for Australian institutional investors following APRA's 2025 guidance on director independence and executive compensation governance — boards that allowed founder-CEO concentration of power without adequate succession planning are now explicitly in the Australian prudential regulator's crosshairs.